Aytu Bioscience Inc (OTCMKTS: AYTU) is likely to have a strong day in the market today, and for good reason. The company announced early this morning that it has received good news from the NASDAQ Capital Market. Here’s what we saw from the announcement:
AYTU To Uplist To The NASDAQ
As mentioned above, Aytu Bioscience is likely to have an incredible day in the market today after the company announced that it has received positive news from the NASDAQ Capital Market. The company, focused on global commercialization of novel products surrounding urology announced that shares of its common stock have been approved for listing on the NASDAQ. As a result, trading on the NASDAQ will commence on Friday, October 20th, 2017 under the symbol AYTU. In a statement, Josh Disbrow, CEO At AYTU, had the following to offer:
“The Company’s listing on the NASDAQ Capital Market is a major milestone for Aytu, and I’m pleased with the progress we have made in the two years since our formation. In a short period of time we’ve successfully built a portfolio of novel, urology-centric products and have scaled a fully-integrated specialty commercial organization. To augment our operational progress, we believe that listing on NASDAQ will help the Company further diversify our shareholder base and provide better liquidity and exposure for the Company as we continue on our growth trajectory.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on AYTU. In particular, we’re interested in following the ongoing work surrounding Natesto, the Japanese commercial launch of Fiera, and the rest of the company’s robust product offering. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!